Afatinib (BIBW 2992) , Targeted Cancer Therapy & Mechanism of Action

Afatinib (BIBW 2992) is a potent, irreversible inhibitor of the ErbB family of tyrosine kinases, including EGFR and HER2, making it an effective targeted therapy for non-small cell lung cancer (NSCLC) patients with specific mutations. Known for its high selectivity and strong antitumor activity, Afatinib offers improved outcomes in cancer treatment by blocking key pathways involved in tumor growth and progression. Shanghai Lizhuo Pharmaceutical Technology Co., Ltd., a reputable manufacturer, supplier, and factory based in China, is dedicated to producing high-quality Afatinib to meet clinical and research demands. Committed to excellence and innovation, Shanghai Lizhuo Pharmaceutical ensures stringent quality control and compliance with international standards, making it a trusted source for pharmaceutical partners worldwide. As a leading China-based supplier, the company provides reliable and consistent Afatinib products, supporting advancements in oncology therapeutics and improving patient care on a global scale.

Related Products